Avian Flu Drug Zanamivir Clears SFDA For Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
A bird flu drug developed by Shanghai Institute of Materia Medica, Nanjing Xian Sheng Dong Yuan Pharmaceutical and Nanjing Yifang Center for Pharmaceutical R&D have passed preclinical appraisal of China's State FDA Center for Drug Evaluation. The zanamivir capsule and its raw material drug received SFDA's approval Nov. 7 to enter clinical trials. Zanamivir, a neuraminidase inhibitor for the treatment of influenza caused by type A virus, is the second most effective avian flu drug after oseltamivir. (Click here for more - Chinese Language)
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.